CN101889999B - Novel pharmaceutical use of kaempferol - Google Patents
Novel pharmaceutical use of kaempferol Download PDFInfo
- Publication number
- CN101889999B CN101889999B CN2010102199740A CN201010219974A CN101889999B CN 101889999 B CN101889999 B CN 101889999B CN 2010102199740 A CN2010102199740 A CN 2010102199740A CN 201010219974 A CN201010219974 A CN 201010219974A CN 101889999 B CN101889999 B CN 101889999B
- Authority
- CN
- China
- Prior art keywords
- kaempferol
- tyrosinase
- effect
- arbutin
- kaempferide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 title claims description 55
- 235000008777 kaempferol Nutrition 0.000 title claims description 27
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 title claims description 26
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 title claims description 26
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 title claims description 26
- 210000002752 melanocyte Anatomy 0.000 claims abstract description 16
- 101710147108 Tyrosinase inhibitor Proteins 0.000 claims abstract description 4
- 230000003101 melanogenic effect Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 22
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 abstract description 22
- 230000002401 inhibitory effect Effects 0.000 abstract description 12
- 102000003425 Tyrosinase Human genes 0.000 abstract description 10
- 108060008724 Tyrosinase Proteins 0.000 abstract description 10
- 229960000271 arbutin Drugs 0.000 abstract description 10
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 abstract description 10
- 210000004027 cell Anatomy 0.000 abstract description 5
- 230000035755 proliferation Effects 0.000 abstract description 4
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 3
- 230000003013 cytotoxicity Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000002087 whitening effect Effects 0.000 abstract description 2
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 abstract 6
- 230000003061 melanogenesis Effects 0.000 abstract 3
- 230000002255 enzymatic effect Effects 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 8
- 208000003351 Melanosis Diseases 0.000 description 7
- 230000036564 melanin content Effects 0.000 description 6
- 206010008570 Chloasma Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 239000007854 depigmenting agent Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- ZHXRTJYHLGJEEE-UHFFFAOYSA-N 2-[(3,4-dihydroxyphenyl)-hydroxymethyl]-2,3-dihydropyrano[2,3-g][1,4]benzodioxin-7-one Chemical compound C1OC2=CC=3OC(=O)C=CC=3C=C2OC1C(O)C1=CC=C(O)C(O)=C1 ZHXRTJYHLGJEEE-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000005405 multipole Effects 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 229940127234 oral contraceptive Drugs 0.000 description 2
- 239000003539 oral contraceptive agent Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- HKIKAXXIWJHWLY-ZIIYPAMZSA-N Aloesin Chemical compound C=12OC(CC(=O)C)=CC(=O)C2=C(C)C=C(O)C=1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HKIKAXXIWJHWLY-ZIIYPAMZSA-N 0.000 description 1
- HKIKAXXIWJHWLY-QEVGBQTESA-N Aloesin Natural products O=C(CC=1Oc2c([C@H]3[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O3)c(O)cc(C)c2C(=O)C=1)C HKIKAXXIWJHWLY-QEVGBQTESA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- XGRYDJSRYGHYOO-UHFFFAOYSA-N Thesine Natural products C1=CC(O)=CC=C1C1C(C(=O)OCC2C3CCCN3CC2)C(C=2C=CC(O)=CC=2)C1C(=O)OCC1C2CCCN2CC1 XGRYDJSRYGHYOO-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- XGRYDJSRYGHYOO-KJYQHMRQSA-N bis[[(1r,8r)-2,3,5,6,7,8-hexahydro-1h-pyrrolizin-1-yl]methyl] 2,4-bis(4-hydroxyphenyl)cyclobutane-1,3-dicarboxylate Chemical compound C1=CC(O)=CC=C1C1C(C(=O)OC[C@H]2[C@H]3CCCN3CC2)C(C=2C=CC(O)=CC=2)C1C(=O)OC[C@H]1[C@H]2CCCN2CC1 XGRYDJSRYGHYOO-KJYQHMRQSA-N 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a kaempferide, which is characterized in that: a tyrosinase inhibitor for inhibiting melanogenesis of normal human melanocytes is a application. The tyrosinase inhibitor has the advantages that: the kaempferide has obvious effect of inhibiting the melanogenesis of the normal human melanocytes and the enzymatic activity of tyrosinase; and the inhibiting effect is better than that of the whitening preparation arbutin well-known in the world, but the influence on cell morphology and proliferation is relatively light, so the kaempferide is an inhibitor which has low cytotoxicity and application prospect and can inhibit the melanogenesis and the enzymatic activity of the tyrosinase.
Description
Technical field
The present invention relates to a kind of purposes of kaempferol, belong to field of traditional Chinese.
Background technology
Most of pigment obstacle dermatoses such as pathogeny such as chloasma, freckle and melanism still imperfectly understand; Wherein the chloasma treatment is the most difficult; And buccal, forehead, upper lip, nose and following chin etc. with face are sent out the zone for good, are mainly caused by inherited genetic factors, ultraviolet radiation, gestation, oral contraceptive or antiepileptic.Be more common in the east young and middle-aged women, its number of the infected accounts for the 0.25-4% of department of dermatologry prescription on individual diagnosis patient number in Southeast Asia, and sickness rate is 50-70% among the anemia of pregnant woman, and oral contraceptive person sickness rate is 8-29%, and the also sustainable existence of mottle after part patient childbirth or the drug withdrawal.Chromatopathys such as chloasma bring very big psychological burden because influence patient's beauty treatment to the patient, and existing medicine for removing speckle has that life cycle is grown, uncertain therapeutic efficacy is cut and defective such as zest is strong.But because its pathogenic factor is unclear fully as yet up to now, also do not have highly effective Therapeutic Method, well-known, owing to the demand of medical cosmetology, Solu-Eze more and more receives people's attention in recent years.Many depigmenting agents have been found at present; But several kinds of depigmenting agents seldom such as Arbutin, methylgenistein and Aloe resin B are only arranged to pigment cell's no cytotoxicity; Other all show cytotoxicity in various degree; And the Solu-Eze of existing no cytotoxicity exists life cycle long; Defectives such as uncertain therapeutic efficacy is cut, zest is strong are not especially received good effect when treatment chloasma etc., therefore seek the striving direction that little, the eutherapeutic depigmenting agent of toxic and side effects becomes researcher.
Method and the medicine of the treatment of most of so far pigment obstacle dermatoses are unsatisfactory, and it is long that ubiquity treatment cycle, and patient dependence is relatively poor, effect instability, curative effect defective such as often vary with each individual.And Chinese medicine accumulated rich experience, and it is low to have toxicity at aspects such as chromatopathy such as treatment chloasma, and characteristics such as determined curative effect receive people's attention just day by day.Research in China Chinese herbal medicine effect historical of long standing and well established, Chinese herbal medicine resource is extremely abundant, and kind surplus medicinal plants has 15,000 approximately, the overwhelming majority are demanded research and development urgently, wherein much are Chinese distinctive medicinal plants.In recent years; China has obtained remarkable progress at the aspects such as development and use of natural resources, and the chemical constitution study of conventional Chinese medicine has been carried out a large amount of work, has obtained important achievement; Therefrom be divided into from identifying thousands of kinds of chemical compounds; Wherein much demonstrate certain biological activity, this has important function to illustrating Effective Components of Chinese Herb and quality control thereof etc., still; The effective substance of most conventional Chinese medicines and mechanism of action thereof cause most of conventional Chinese medicine drug effects not clear as yet not by deep research.And herbal medicine efficacy shortage modern science representation language, thereby be difficult for being understood.Therefore utilize modern science and technology to set up biological activity model or target spot, the mechanism of action of utilization modern science language performance Chinese medicine, thus let the world understand Chinese medicine better.The medicine of in recent years, from plant amedica, seek low toxicity, treating pigmented dermatosis has efficiently become the focus of people's research.
Summary of the invention
The purpose of this invention is to provide that a kind of toxicity is low, synthetic to the normal human melanocytes melanocyte, tyrosinase activity has the obvious suppression effect, and effect is superior to the purposes of the melanogenic kaempferol of inhibition normal human melanocytes of arbutin.
The purposes of kaempferol of the present invention is to suppress the application of the melanogenic tyrosinase inhibitor of normal human melanocytes as preparation.
Kaempferol is called kaempferol, campherol, Rhizoma Kaempferiae flavonol and kaempferol, maoyancaosu, thesine etc. again.Kaempferol is one of active component of many plants such as Rhizoma Kaempferiae rhizome, Sophora japonica L. fruit, Herba Hyperici, Stigma Croci; Have antibiotic; Antiinflammatory and press down enzyme effect (suppressing an eye aldose reductase activity), and can improve the anti-tumor property (anti-skin carcinoma) of mice, but antiulcer and suppress the activity of hiv protease also; Kaempferol can extract at laboratory, also can directly buy from market, as: the green clear biological engineering company limited in Shaanxi (address: one tunnel No. 177 A5404 in Fengcheng City, Xi'an) just have kaempferol to sell.
Advantage of the present invention is: kaempferol is synthetic to the normal human melanocytes melanocyte, tyrosinase activity has the obvious suppression effect; And being eager to excel of the preparation arbutin of whitening that inhibitory action is generally acknowledged now in the world; But the form of pair cell and the influence of propagation are lighter; Therefore explain that kaempferol is that a kind of cytotoxicity is less, the synthetic inhibitor with tyrosinase activity of application prospect melanocyte is arranged.
The specific embodiment
We find that the mode that kaempferol relies on concentration suppresses the activity of Mushroom Tyrosinase when utilizing Mushroom Tyrosinase DOPA speed oxidizing process to measure the variable concentrations kaempferol to the activity influence of Mushroom Tyrosinase, and inhibitory action reaches the highest during with 500 μ M.Then the normal human melanocytes during we cultivate with the kaempferol intervention, observe it to the melanocyte tyrosinase activity, melanocyte is synthetic and the influence of cell proliferation, the result shows the rising along with kaempferol concentration, and the maximum inhibition of TYR is strengthened gradually; Along with the prolongation of action time, the kaempferol of same concentrations is also strengthened the active inhibitory action of TYR.Inhibition to melanin content also is to strengthen gradually, and along with the prolongation of action time, the kaempferol of same concentrations is also strengthened the inhibitory action of melanin content.Compare with another kind of skin-whitening agents arbutin, the kaempferol group effect 48 of 10,25,50,75,100 μ moL, 72h obviously strengthen than arbutin the inhibitory action of TYR, and be the most obvious with 72h.Kaempferol has inhibitory action to melanin content; Compare with arbutin; Though the arbutin group also has inhibitory action and presents dose-effect and time-effect relationship melanin content; But the arbutin group is starkly lower than the kaempferol experimental group to the inhibition strength of melanin content, and is the most obvious to the inhibitory action of melanin content at the kaempferol group effect 48h of 10,25,50,75,100 μ moL.Kaempferol has short proliferation function to MC.Effect strengthens during 1 μ moL, when 5 μ moL, the MC proliferation function is obviously suppressed, but the kaempferol of 5,10,50,100 μ moL is to increase with concentration, and is in rising trend to the rate of increase of MC, the strongest in the 48h effect.Compare with arbutin, arbutin is along with concentration increases obvious more for the rate of increase inhibitory action of MC.But along with its concentration increases and the prolongation of action time, melanocytic dendron is obvious by the multipole trend that transforms to the two poles of the earth, and cell grows fine.Cell proliferation not necessarily is directly proportional with the amount of melanocyte, and more close with the variation relation of melanocyte dendron, and the melanocytic melanocyte synthetic quantity in the two poles of the earth is than low many of multipole melanocyte; The synthetic activity with tryrosinase of melanocyte is proportionate.We think short proliferation function and the active result of its restraint of tyrosinase contradiction not of kaempferol performance, and kaempferol is in higher concentration during like 500 μ moL, and the cell growing way is still good.And arbutin cell growing way when 50 μ moL is poorer than 500 μ moL kaempferols.
Claims (1)
1. the purposes of a kaempferol is characterized in that: suppress the application of the melanogenic tyrosinase inhibitor of normal human melanocytes as preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102199740A CN101889999B (en) | 2010-06-25 | 2010-06-25 | Novel pharmaceutical use of kaempferol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102199740A CN101889999B (en) | 2010-06-25 | 2010-06-25 | Novel pharmaceutical use of kaempferol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101889999A CN101889999A (en) | 2010-11-24 |
| CN101889999B true CN101889999B (en) | 2012-07-18 |
Family
ID=43099459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102199740A Expired - Fee Related CN101889999B (en) | 2010-06-25 | 2010-06-25 | Novel pharmaceutical use of kaempferol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101889999B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1443056A (en) * | 2000-07-19 | 2003-09-17 | 株式会社资生堂 | External preparations for beautifying skin |
-
2010
- 2010-06-25 CN CN2010102199740A patent/CN101889999B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1443056A (en) * | 2000-07-19 | 2003-09-17 | 株式会社资生堂 | External preparations for beautifying skin |
Non-Patent Citations (1)
| Title |
|---|
| 王芳.桑叶中酪氨酸酶抑制成分的研究.《浙江工商大学博士学位论文》.2009,参见第95页第2段，图4-1、4-2. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101889999A (en) | 2010-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106214592B (en) | Hair follicle nutrient liquor composition and preparation method thereof | |
| US20170172183A1 (en) | Whitening composition and the use thereof | |
| CN103656303A (en) | Traditional Chinese medicine capsule with function of reducing blood pressure and preparation method of traditional Chinese medicine capsule | |
| KR101073678B1 (en) | Shampoo composition using medical herbs and manufacturing method thereof | |
| CN110123683A (en) | Compound natural small molecule plant extracts phalacrosis prevention and hair generation prescription and products thereof | |
| CN102038626A (en) | Traditional Chinese medicinal hair-restoring and anti-alopecia shampoo and preparation method thereof | |
| CN106880693A (en) | It is a kind of to treat hair growth liquor composition of alopecia seborrheica and preparation method thereof | |
| CN105078863A (en) | Whitening and freckle removing lotion and preparation method thereof | |
| CN106852827A (en) | A kind of compound method of cleawhite pack | |
| CN112842923A (en) | Scalp nutrient solution composition and preparation method thereof | |
| CN108815088A (en) | A kind of phalacrosis prevention and hair generation shampoo and preparation method thereof | |
| CN103432227B (en) | Anti-hair loss Chinese herb compound of antagonism expression of androgen receptor and preparation method thereof | |
| CN102113993B (en) | Fine jade square and preparation method and application thereof | |
| CN102335231B (en) | Chinese medicinal moisturizing cream for treating chloasma as well as preparation method and application thereof | |
| CN101933984A (en) | Liniment formula for blackening hair and preventing hair loss and preparation and using methods thereof | |
| CN101889999B (en) | Novel pharmaceutical use of kaempferol | |
| CN104983817B (en) | A kind of tincture for treating alopecia seborrheica and preparation method thereof | |
| CN106138477A (en) | A kind of pharmaceutical composition for skin speckle dispelling and preparation method thereof | |
| CN105078862A (en) | Whitening and freckle removing facial mask and preparation method thereof | |
| CN101703461A (en) | Skin-whitening speckle-removing cream and preparation method thereof | |
| CN106943492A (en) | One kind prevents white hair blackening liquid composition and preparation method thereof | |
| CN103330850A (en) | Traditional Chinese medicine for treating acne | |
| CN113599472A (en) | Traditional Chinese medicine preparation for treating seborrheic alopecia and preparation method and application thereof | |
| CN103169630A (en) | Mosquito repellent shampoo | |
| CN102475646A (en) | Dark plum lemon whitening skin care liquid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120718 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |